developed miR-497-loaded exosomes as a potential therapy for the treatment of NSCLC, based on the fact that miR-497 has anti-angiogenic and anti-tumor effects by suppressing the expression of Cyclin E1 (CCNE1) along with HDGF (Hepatoma-derived growth factor), YAP1 (Yes-associated protein 1), and VEGF-A (Vascular endothelial growth factor-A). The gene discussed is VEGFA; the disease is neoplasm.